Ensysce reports third-quarter 2026 results as CY200 regulatory review continues
Ensysce Biosciences completed its Cy Biopharma acquisition, submitted the CY200 Phase 2a protocol in the UK and completed enrollment in the final stage of PF614-MPAR-102 during the third quarter of 2026.
Ensysce Biosciences, Inc. (NASDAQ:ENSC) reported its financial and operating results for the third quarter ended September 30, 2026, highlighting the completed acquisition of Cy Biopharma, progress toward a UK study of CY200 and completed enrollment in the final stage of its PF614-MPAR-102 study.
Ensysce completed its acquisition of Cy Biopharma in August 2026. The transaction added CY200, a clinical-stage neuroplastogenic candidate for Complex Regional Pain Syndrome (CRPS), to Ensysce’s pipeline. The company said the active ingredient in CY200 has received FDA Orphan Drug Designation.
CY200 is a psilocybin-predominant botanical extract being developed for CRPS, a severe chronic pain disorder for which there is currently no FDA-approved therapy. Its development follows an observational pilot study funded by Cy Biopharma.
#CY200 protocol receives request for more information
In September 2026, Ensysce submitted the CYBIO 001 Phase 2a protocol in the UK for review by the Medicines and Healthcare products Regulatory Agency (MHRA) and a research ethics committee.
The planned study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group proof-of-concept trial. It is designed to assess the efficacy, safety and tolerability of CY200 compared with placebo in adult participants with CRPS Type 1.
On November 6, 2026, the MHRA and the research ethics committee requested additional information in support of the clinical trial application. Ensysce said it was preparing a response for the MHRA’s consideration. The company said it intends to prepare its sites and clinical team to begin enrollment once UK regulatory clearance is received.
Ensysce completed enrollment in Part 3 of the PF614-MPAR-102 study in August 2026. The company described Part 3 as the final stage of the study, with work focused on PF614-MPAR’s protective profile across dosing scenarios and the effect of food on analgesia delivery and overdose protection.
PF614 is being developed as an extended-release oxycodone product using trypsin-activated abuse protection. Ensysce says the product remains inactive until exposure to trypsin in the small intestine, where it is designed to release oxycodone in a controlled manner.
PF614-MPAR combines PF614 with Ensysce’s Multi-Pill Abuse Resistance technology and has FDA Breakthrough Therapy designation. The company is also continuing the pivotal PF614-301 Phase 3 trial, which evaluates PF614 for moderate to severe pain following abdominoplasty.
The PF614-MPAR-102 study is supported by a $15.1 million multi-year NIDA award. Ensysce said $2.7 million remained available as of September 30, 2026, for completion of the study and long-term non-clinical studies required for an eventual New Drug Application.
Cash and cash equivalents stood at $29.7 million as of September 30, 2026, compared with $4.3 million as of December 31, 2025. Ensysce attributed the increase to $21.1 million of net cash provided by financing activities, including $19.6 million of net proceeds from the Series C private placement, and $11.4 million of net cash acquired from Cy Biopharma. These inflows were partly offset by $6.9 million used in operating activities during the first nine months of 2026.
Federal grant funding was $2.2 million in the third quarter of 2026, compared with $0.5 million in the comparable quarter of 2025. Research and development expenses rose to $3.2 million from $3.0 million, while general and administrative expenses increased to $1.6 million from $1.3 million. Ensysce attributed both expense increases primarily to costs associated with the Cy Biopharma acquisition.
The acquisition also produced a one-time non-cash charge of approximately $79.9 million for acquired in-process research and development, mainly related to CY200. Net loss attributable to common stockholders was $82.3 million for the third quarter of 2026, compared with $3.7 million in the third quarter of 2025. The 2026 loss also included a $0.2 million deemed dividend connected with the retirement of Series B Preferred Stock.
Ensysce said continued research and development aimed at regulatory approval is expected to result in losses for the foreseeable future. The company also identified risks involving possible Nasdaq delisting, stockholder approval for conversion of Series C non-voting convertible preferred stock, the ability to manage expenses and obtain additional capital, and the continuation of government funding.
Other stated risks include delays or unsuccessful results in clinical development, regulatory approval uncertainties connected with product candidates, the MHRA request for more information on the CY200 application, failure to achieve the clinical trial milestone connected with the Series C private placement and the possibility that anticipated benefits of the Cy Biopharma acquisition may not be realised.
Ensysce completed its August 2026 acquisition of Cy Biopharma, adding CY200 for CRPS to its pipeline.
The CYBIO 001 Phase 2a protocol was submitted in the UK, but regulators requested additional information on November 6, 2026.
Enrollment was completed in Part 3, the final stage of the PF614-MPAR-102 study.
Cash and cash equivalents were $29.7 million as of September 30, 2026.
Net loss attributable to common stockholders was $82.3 million, including an approximately $79.9 million non-cash acquired research and development charge.
Ensysce Biosciences reported its financial and operational results for the third quarter ended September 30, 2026. The company highlighted the completed acquisition of Cy Biopharma, submission of the CY200 Phase 2a protocol to the UK Medicines and Healthcare products Regulatory Agency, completion of enrolment in the final stage of the PF614-MPAR-102 study and $29.7 million of cash and cash equivalents at quarter-end.
Ensysce Biosciences’ results cover the third quarter ended September 30, 2026. The cash flow figures presented in the release cover the nine months ended September 30, 2026.
CY200 became Ensysce Biosciences’ lead pipeline asset following its completed acquisition of Cy Biopharma in August 2026. CY200 is a psilocybin-predominant botanical extract being developed for Complex Regional Pain Syndrome, and its active ingredient has received FDA Orphan Drug Designation.
Ensysce Biosciences submitted the CYBIO 001 Phase 2a protocol in the UK in September 2026 for review by the Medicines and Healthcare products Regulatory Agency and a research ethics committee. On November 6, 2026, the reviewing authorities requested additional information, and the company said it was preparing its response for the MHRA’s consideration.
The CYBIO 001 trial is designed to evaluate the efficacy, safety and tolerability of CY200 compared with placebo in adult participants with Complex Regional Pain Syndrome Type 1. Ensysce Biosciences describes it as a multicentre, randomised, double-blind, placebo-controlled, parallel-group, proof-of-concept study to be conducted in the UK.
Ensysce Biosciences completed enrolment in Part 3, the final stage of the PF614-MPAR-102 study, in August 2026. The part was designed to further characterise PF614-MPAR’s protective profile across a full range of dosing scenarios and evaluate the effect of food on the delivery of analgesia and overdose protection.
Ensysce Biosciences describes PF614 as a next-generation extended-release oxycodone with trypsin-activated abuse protection, designed to release oxycodone in a controlled manner after exposure to trypsin in the small intestine. PF614-MPAR combines PF614 with the company’s Multi-Pill Abuse Resistance technology and has received FDA Breakthrough Therapy designation; it is being developed with built-in protection against oral overdose.
Ensysce Biosciences had $29.7 million in cash and cash equivalents as of September 30, 2026, compared with $4.3 million as of December 31, 2025. The company said the increase reflected $21.1 million of net cash provided by financing activities, primarily $19.6 million of net proceeds from the Series C private placement, and $11.4 million of net cash acquired from Cy Biopharma, partly offset by $6.9 million used in operating activities during the first nine months of 2026.
Research and development expenses were $3.2 million in the third quarter of 2026, compared with $3.0 million in the same period in 2025. General and administrative expenses were $1.6 million, compared with $1.3 million in the third quarter of 2025; Ensysce Biosciences attributed both increases primarily to incremental expenses from the Cy Biopharma acquisition.
Ensysce Biosciences reported a net loss attributable to common stockholders of $82.3 million for the third quarter of 2026, compared with $3.7 million for the third quarter of 2025. The 2026 loss included an approximately $79.9 million one-time non-cash charge for acquired in-process research and development and a $0.2 million deemed dividend related to the retirement of the Series B Preferred Stock.
The PF614-MPAR-102 study is funded through Ensysce Biosciences’ $15.1 million multi-year NIDA award. The company said $2.7 million remained available as of September 30, 2026, to support completion of the study and the long-term non-clinical studies required for an eventual New Drug Application.
Chief Executive Officer Dr. Lynn Kirkpatrick said Ensysce Biosciences’ focus was on initiating the CY200 Phase 2a study and delivering on the milestones ahead. President James Morrison said the company was preparing its sites and clinical team to be ready to commence enrolment once practicable after receiving regulatory clearance in the UK.
Ensysce Biosciences is a clinical-stage biotechnology company developing neuroplastogenic therapies beyond mood disorders, with an initial focus on Complex Regional Pain Syndrome. It is also developing novel opioids for severe pain while seeking to minimise the risks of drug abuse and overdose.
Ensysce Biosciences identifies its shares as trading on Nasdaq under the ticker symbol NASDAQ:ENSC.
Ensysce Biosciences identified risks including possible Nasdaq delisting, the need for stockholder approval for conversion of the Series C non-voting convertible preferred stock, the ability to manage expenses and obtain sufficient additional capital, and delays or unsuccessful results in clinical development and regulatory approval. The company also identified risks related to the MHRA’s request for additional information on the CY200 application, continuation of government funding, the PF614-MPAR-102 clinical trial milestone for the Series C private placement and failure to realise anticipated benefits from the acquisition.